Dupuytren's Contracture

Table of Contents

  1. Overview
  2. Pathophysiology and Histology
  3. Stages of Disease
  4. Risk Factors and Associations
  5. Clinical Presentation and Diagnosis
  6. Non-Surgical Management
  7. Surgical and Procedural Treatment
  8. Recurrence and Long-Term Outcomes
  9. Key Research Papers
  10. PubMed Research Searches
  11. Connections
  12. Featured Videos

Overview

Dupuytren's contracture is a fibroproliferative disease of the palmar fascia that causes the connective tissue beneath the skin of the palm to thicken and scar, progressively pulling one or more fingers into a bent (flexed) position that cannot be straightened. It is not a tendon problem — the tendons themselves are unaffected; the disease involves the tough fascial tissue that overlies them.

The condition is most common in men over age 40 of Northern European descent. The ring finger (4th) and little finger (5th) are most commonly affected, though the middle finger and, rarely, the index finger can also be involved. About 50% of cases are bilateral, though often asymmetric in severity. The condition is typically painless once established, though early nodules may be mildly tender.

A simple bedside assessment is the tabletop test (also called the Hubbard sign): the patient tries to lay their hand completely flat on a table. If the palm and all fingers cannot make full contact with the table surface, the test is positive, indicating clinically significant contracture. Severity is formally graded using the Tubiana scale (grades 0–4) based on the total passive extension deficit measured across the affected finger's joints.

The condition is named after Baron Guillaume Dupuytren, the French surgeon who performed the first documented surgical fasciectomy for the condition in 1831 at the Hôtel-Dieu hospital in Paris — though earlier descriptions exist, including by Henry Cline Sr. and Astley Cooper. Dupuytren's condition is sometimes called morbus Dupuytren, palmar fibromatosis, or palmar fascial contracture.

Back to Table of Contents

Pathophysiology and Histology

Myofibroblast proliferation is the central cellular event in Dupuytren's contracture. Normal palmar fascial fibroblasts transform into myofibroblasts — cells that express alpha-smooth muscle actin (α-SMA) and have the contractile properties of smooth muscle while still producing extracellular matrix like fibroblasts. This transformation is driven primarily by TGF-β1 (transforming growth factor beta-1), along with PDGF (platelet-derived growth factor), and local mechanical stress. The result is a self-amplifying cycle: myofibroblasts contract, increasing local tension, which further stimulates TGF-β1 signaling, recruiting more myofibroblasts.

These activated myofibroblasts deposit excess extracellular matrix, particularly an abnormal ratio of type III collagen (fetal-type, more flexible) in early disease that later shifts toward type I collagen (mature, stiff, inextensible) as the disease matures. This collagen deposition within the normal palmar aponeurosis transforms the fascial bands into pathological cords that progressively shorten.

Histological Phases (Luck's Classification, 1959)

Anatomy of the Pathological Cords

The normal palmar aponeurosis has defined band structures; in Dupuytren's disease these become pathological cords. The most clinically important cord types are:

Back to Table of Contents

Stages of Disease

Dupuytren's contracture evolves through recognizable clinical stages, though the pace varies enormously between patients. Some individuals progress from nodule to significant contracture within months; others remain at the nodule stage for decades.

Stage 1 — Nodule Formation

The first detectable sign is a painless, firm palmar nodule located in the distal palm, typically in line with the ring or little finger ray. The nodule represents the myofibroblast-rich proliferative phase. It may be mildly tender when first forming but typically becomes asymptomatic. The overlying skin may be puckered or dimpled due to tethering of the skin to the fascia through vertical fascial septa. No contracture is present at this stage.

Stage 2 — Cord Formation

The nodule matures into a fibrotic cord as myofibroblasts align along fascial planes and deposit oriented collagen. The cord becomes palpable as a firm, longitudinal band extending from the palm into the digit. The skin overlying the cord is often tethered. At this stage, the finger may have a very mild tendency toward flexion, but full passive extension is still possible.

Stage 3 — Finger Contracture

As the cord shortens, it pulls the affected finger(s) progressively into flexion. MCP joint contractures develop first. Functionally, MCP contractures up to 60–70° are often well tolerated — the hand can still grip objects reasonably well. PIP joint contractures develop later and are much more functionally disabling. They also respond less well to all forms of treatment, because the PIP joint capsule, volar plate, and flexor tendon sheath undergo secondary contracture once the joint has been held in flexion for an extended period.

Severity is classified using the Tubiana Grading Scale based on the total passive extension deficit (TPED) across the affected ray's joints:

Stage 4 — Functional Impairment

With significant contracture, the tabletop test is clearly positive (cannot lay the hand flat). Grip strength is reduced. Patients have difficulty with: wearing gloves, shaking hands, reaching into pockets, gripping large tools or steering wheels, playing a musical instrument, and washing the face. PIP contractures of 30° or more in the ring or little finger are typically sufficient to motivate patients to seek treatment.

Back to Table of Contents

Risk Factors and Associations

Demographic and Genetic Factors

Medical and Lifestyle Risk Factors

Dupuytren's Diathesis

The Dupuytren's diathesis concept describes a phenotype associated with particularly aggressive disease, early onset, and high recurrence after treatment. Features of Dupuytren's diathesis include:

Patients with multiple diathesis features have a significantly higher rate of recurrence after all forms of treatment, and this knowledge should inform pre-operative counseling and treatment choice.

Back to Table of Contents

Clinical Presentation and Diagnosis

Dupuytren's contracture has a typically insidious onset. Most patients first notice a painless lump in the palm, often incidentally or when a family member points it out. Over months to years, one or more fingers progressively flex and cannot be fully straightened. The onset is rarely acute. Pain at presentation should raise suspicion for an alternative diagnosis.

Physical Examination

The diagnosis is entirely clinical — no laboratory tests, X-rays, or imaging studies are required or diagnostically useful in typical cases. Key examination steps:

Differential Diagnosis

Back to Table of Contents

Non-Surgical Management

No pharmacological agent has been conclusively proven to halt or reverse established Dupuytren's contracture. Management options at the early nodule stage are limited, and the primary role of the physician is accurate diagnosis, patient education, and monitoring.

Observation and Monitoring

Observation alone is appropriate for patients with Tubiana grade 0–I disease without functional impairment. Many patients remain stable at the nodule stage for years or decades. The tabletop test should be performed at each visit as a simple progression monitor. Patients should be counseled on the features of Dupuytren's diathesis that predict faster progression.

Pharmacological Agents (Not Proven Effective)

Multiple agents have been studied for disease modification in Dupuytren's, none with robust evidence:

Radiotherapy

External beam radiotherapy (XRT) has the strongest evidence among non-surgical options for early Dupuytren's disease (nodule and early cord stage, Tubiana grade 0–N). The standard protocol is approximately 30 Gy delivered in 5 fractions. Seegenschmiedt and colleagues have published the largest series, demonstrating that radiotherapy significantly slows progression and can soften nodules in early disease. The mechanism is likely suppression of myofibroblast proliferation by ionizing radiation. Radiotherapy is not effective for established contracture (it does not lyse existing cords) and is not widely available. It is best considered for patients with early disease who wish to delay or avoid surgery, particularly younger patients and those with diathesis features.

Physiotherapy and Splinting

No evidence supports physiotherapy or stretching exercises as disease-modifying for Dupuytren's contracture. Night splinting post-operatively is used in some protocols to maintain extension gains from surgery, though its benefit is debated in the literature. Pre-operatively, splinting does not reverse contracture.

Back to Table of Contents

Surgical and Procedural Treatment

Treatment is indicated when Dupuytren's contracture causes functional impairment. The general thresholds are: MCP contracture of 30–40° or more, or any PIP contracture (since PIP contractures are harder to correct and the joint undergoes secondary capsular contracture the longer it is held in flexion). Three main procedural options exist, each with a different recurrence-versus-invasiveness trade-off.

1. Needle Aponeurotomy (NA) / Percutaneous Needle Fasciotomy (PNF)

An office-based procedure performed under local anesthesia. A needle (typically a standard hypodermic needle, 16–18 gauge) is used to repeatedly score and perforate the cord under the skin until it ruptures and the finger can be extended. Requires no incision beyond the needle puncture. Recovery is rapid — most patients return to normal activities within days.

2. Collagenase Clostridium histolyticum (CCH, Xiaflex)

CCH is a purified enzyme derived from Clostridium histolyticum bacteria that preferentially degrades the collagen within the Dupuytren's cord. It was FDA-approved in 2010 for Dupuytren's contracture following the pivotal CORD I and CORD II trials.

Procedure: The enzyme is injected directly into the cord in an office setting. The patient returns 24–72 hours later (typically the next day) for a gentle manipulation under local anesthesia to rupture the weakened cord and extend the finger. A splint is often worn for 4 months afterward.

3. Limited (Selective) Fasciectomy

Surgical removal of the diseased fascia while preserving normal palmar and digital structures. Performed under general or regional anesthesia as a day surgery procedure. The standard incision is a zigzag (Bruner) incision over the palm and digit, which provides wide exposure while crossing skin tension lines to minimize scarring. The surgeon excises the diseased cords under direct vision, with careful preservation of the digital neurovascular bundles — particularly important when a spiral cord is present, as the digital nerve and artery are displaced into the surgical danger zone.

4. Dermofasciectomy

The most radical procedure: excision of the diseased fascia plus the overlying skin, which is replaced with a full-thickness skin graft (typically from the ipsilateral inner arm). The rationale is that diseased skin may harbor fibroblast progenitors capable of re-initiating the fibroproliferative process; removing it reduces recurrence risk.

Back to Table of Contents

Recurrence and Long-Term Outcomes

Recurrence after treatment is one of the defining challenges of Dupuytren's contracture management. Dupuytren's disease recurs — it is not cured by any current intervention; only the affected tissue is removed or disrupted, while the underlying genetic and systemic predisposition remains.

Recurrence Rates by Treatment

PIP Joint Outcomes

PIP joint contractures are consistently harder to correct and less likely to achieve full extension after any treatment compared to MCP contractures. This is because the PIP joint, once held in flexion for extended periods, develops secondary changes: the volar plate and joint capsule shorten, the check-rein ligaments contract, and the accessory collateral ligaments tighten. Even after complete cord removal or disruption, the joint itself may have a fixed component that is not correctable without additional capsular release — a more complex procedure with higher complication risk. This is a key argument for treating PIP contractures earlier rather than waiting until they are severe.

Dupuytren's Diathesis and Recurrence

Patients who present with Dupuytren's diathesis features — early onset, bilateral disease, ectopic fibromatoses (Ledderhose, Peyronie's, Garrod's pads), male sex, family history — have substantially higher recurrence rates and should be counseled accordingly. In high-diathesis patients, dermofasciectomy or repeated procedures over a lifetime are often the realistic expectation.

Adjuvant Therapies After Surgery

Post-operative measures studied for recurrence prevention include: corticosteroid injection into residual nodules, radiotherapy to surgical sites, and 5-fluorouracil. None have robust Level I evidence for routine use. Post-operative hand therapy and splinting are standard for recovery, though their effect on recurrence specifically is debated.

Natural History Without Treatment

Dupuytren's disease generally progresses slowly over many years, though the pace is highly variable. Some patients with early nodules remain stable for decades. Others progress rapidly from nodule to severe contracture within 1–2 years. The presence of Dupuytren's diathesis features is the best predictor of rapid progression. Observational studies confirm that once PIP contracture is established and severe, complete correction even with surgery is unlikely, underscoring the importance of timely intervention.

Back to Table of Contents

Key Research Papers

  1. Peimer CA et al. (CORD I trial) — Collagenase Clostridium histolyticum for Dupuytren's contracture: comparison of two non-surgical treatment approaches. J Hand Surg Am. 2013. PMID 24581740 — Randomized controlled trial; CCH non-inferior to fasciectomy in contracture correction at 3 months; higher recurrence with CCH at follow-up.
  2. Hindocha S et al. — Dupuytren's diathesis revisited: evaluation of prognostic indicators for risk of disease recurrence. J Hand Surg Am. 2012. PMID 21764508 — Quantifies diathesis risk factors for post-surgical recurrence; bilateral disease, ectopic fibromatoses, and male sex are the strongest predictors.
  3. Townley WA et al. — Dupuytren's contracture unfolded. BMJ. 2006. PMID 16614000 — Systematic review of epidemiology, pathophysiology, clinical features, and treatment options; widely cited overview.
  4. Hurst LC et al. — Injectable collagenase Clostridium histolyticum for Dupuytren's contracture. N Engl J Med. 2009. PMID 19793723 — FDA pivotal trial; 64% MCP and 31% PIP contracture success; established CCH as the first non-surgical pharmacological treatment.
  5. van Rijssen AL et al. — Five-year results of a randomized clinical trial on treatment in Dupuytren's disease: needle aponeurotomy versus limited fasciectomy. Plast Reconstr Surg. 2012. PMID 22373978 — RCT with 5-year follow-up; recurrence rate 85% (NA) vs 21% (fasciectomy); NA appropriate for selected patients accepting higher recurrence.
  6. McFarlane RM — Patterns for the diseased fascia in the fingers in Dupuytren's contracture: displacement of the neurovascular bundle. Plast Reconstr Surg. 1974. PMID 4817795 — Classic anatomical description of cord types including the spiral cord and neurovascular bundle displacement; foundational for surgical safety.
  7. Luck JV — Dupuytren's contracture: a new concept of the pathogenesis correlated with surgical management. J Bone Joint Surg Am. 1959. PMID 13664833 — Original description of the three histological phases (proliferative, involutional, residual); cornerstone of Dupuytren's pathology understanding.
  8. Seegenschmiedt MH et al. — Radiotherapy for early-stage Dupuytren's contracture: long-term results after 13 years follow-up. Strahlenther Onkol. 2001. PMID 27573959 — Systematic review; radiotherapy slows nodule progression and softens early disease; not effective for established contracture.
  9. Nordenskjöld J et al. — Long-term outcomes after dermofasciectomy for Dupuytren's contracture. J Hand Surg Eur. 2017. PMID 29048800 — Dermofasciectomy achieves lowest recurrence (~8% at 5 yr); recommended for high-diathesis and recurrent cases.
  10. Werker PM et al. — Consensus on a multidisciplinary treatment guideline for Dupuytren disease: the 2012 European Consensus. Plast Reconstr Surg Glob Open. 2013. PMID 27553047 — International Dupuytren Society consensus; treatment decision algorithm based on joint, grade, diathesis, and patient factors.
  11. Denkler K — Surgical complications associated with fasciectomy for Dupuytren's disease: a 20-year review of the English literature. Eplasty. 2010. PMID 20596236 — Comprehensive complication analysis; CRPS, nerve injury, and wound dehiscence rates by procedure type; informs consent discussions.
  12. Sweet S, Blackmore S — Surgical and therapy update on the management of Dupuytren's disease. J Hand Ther. 2014. PMID 24930017 — Practical review of surgical indications, the tabletop test as decision threshold, and post-operative therapy protocols.

Back to Table of Contents

PubMed Research Searches

Search PubMed directly for the latest peer-reviewed studies on Dupuytren's contracture:

  1. Dupuytren's contracture treatment options surgical
  2. Dupuytren collagenase Xiaflex CCH outcomes
  3. Dupuytren fasciectomy recurrence rates
  4. Dupuytren needle aponeurotomy technique
  5. Dupuytren diathesis risk factors recurrence
  6. Dupuytren palmar fibromatosis myofibroblast pathophysiology
  7. Dupuytren radiotherapy early disease
  8. Dupuytren epidemiology Northern European prevalence
  9. Peyronie Ledderhose Dupuytren association
  10. Dupuytren dermofasciectomy outcomes
  11. Dupuytren TGF-beta collagen fibrosis mechanism
  12. Dupuytren contracture functional outcomes

Back to Table of Contents

Connections

Back to Table of Contents